Department of Gynaecological Oncology, The Pan-Birmingham Gynaecological Cancer Centre, Sandwell and West Birmingham NHS Trust, Birmingham, UK.
Department of Gynaecological Oncology, Chelsea and Westminster NHS Foundation Trust, Imperial College, London, UK.
Eur J Surg Oncol. 2021 Jun;47(6):1233-1243. doi: 10.1016/j.ejso.2020.12.001. Epub 2020 Dec 5.
One Step Nucleic Acid Amplification (OSNA) assay has recently emerged as a rapid molecular diagnostic tool for the detection of lymph node (LN) metastases. It is a molecular technique that analyses the entire LN tissue using a reverse-transcriptase loop-mediated isothermal amplification reaction to detect tumour specific cytoceratin 19 mRNA.
To ascertain the diagnostic accuracy of OSNA assay in detecting LN metastases amongst different types of malignancy.
We systematically searched MEDLINE, SCOPUS, ClinicalTrials.gov, and Cochrane Database, from inception up to August 2020. Quality assessment was performed using the Modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). We calculated pooled diagnostic indices using the random-effects model. Meta-regression and sub-group analyses were performed to address heterogeneity.
31 studies were included in this meta-analysis, including four different types of cancer. The risk of bias and the overall quality of included studies was moderate to high. There was no evidence of publication bias. The pooled diagnostic odds ratio (DOR) for detecting LN metastases in gynaecological, head & neck/thyroid, gastrointestinal and lung cancer were 100.38, 76.17, 275.14, and 305.84, respectively.
Our findings suggest that OSNA assay had a high diagnostic accuracy in detecting metastatic LNs in different types of malignancy. This evidence is constrained by the limited studies available for few tumour types and the rather high heterogeneity for few outcomes.
一步法核酸扩增(OSNA)检测法最近作为一种快速分子诊断工具,用于检测淋巴结(LN)转移。这是一种分子技术,通过逆转录环介导等温扩增反应分析整个 LN 组织,以检测肿瘤特异性细胞角蛋白 19 mRNA。
确定 OSNA 检测法在检测不同类型恶性肿瘤中的 LN 转移的诊断准确性。
我们系统地检索了 MEDLINE、SCOPUS、ClinicalTrials.gov 和 Cochrane 数据库,检索时间截至 2020 年 8 月。使用修改后的诊断准确性研究质量评估(QUADAS-2)进行质量评估。我们使用随机效应模型计算了汇总诊断指数。进行了荟萃回归和亚组分析以解决异质性。
本荟萃分析共纳入 31 项研究,包括四种不同类型的癌症。纳入研究的偏倚风险和整体质量为中等到较高。未发现发表偏倚的证据。在妇科、头颈部/甲状腺、胃肠道和肺癌中检测 LN 转移的汇总诊断优势比(DOR)分别为 100.38、76.17、275.14 和 305.84。
我们的研究结果表明,OSNA 检测法在检测不同类型恶性肿瘤中的转移性 LN 具有较高的诊断准确性。这种证据受到几个肿瘤类型的研究数量有限以及几个结果的高度异质性的限制。